A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2016
Price : $35 *
At a glance
- Drugs Elgemtumab (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 20 Apr 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
- 20 Apr 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 11 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.